Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

80.70USD
16 Feb 2018
Change (% chg)

$-0.85 (-1.04%)
Prev Close
$81.55
Open
$81.45
Day's High
$82.33
Day's Low
$80.61
Volume
7,548,648
Avg. Vol
8,680,486
52-wk High
$89.54
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.24
Market Cap(Mil.): $105,388.20
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.57
Yield (%): 2.80

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

12:20pm EST

UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

12:18pm EST

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

9:41am EST

Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

LONDON GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division.

Feb 08 2018

UPDATE 1-Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

* GSK shares up 2.7 percent (Adds context on other challengers, GSK shares)

Feb 08 2018

BRIEF-GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences

* GLAXOSMITHKLINE PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​ Source text for Eikon: Further company coverage:

Feb 08 2018

BRIEF-Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir

* Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada

Feb 08 2018

U.S. FDA approves Gilead triple HIV drug, rival files lawsuit

The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

Feb 07 2018

UPDATE 4-U.S. FDA approves Gilead triple HIV drug, rival files lawsuit

Feb 7 The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

Feb 07 2018

CORRECTED-U.S. FDA approves Gilead's three-drug HIV regimen

Feb 7 The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences Inc's three-drug regimen to treat HIV-1 infection.

Feb 07 2018

Earnings vs. Estimates